Teva Pharma stock gets Buy rating from Goldman Sachs on positive drug data
PositiveFinancial Markets

Teva Pharma's stock has received a 'Buy' rating from Goldman Sachs following promising data on its latest drug. This endorsement is significant as it reflects investor confidence in Teva's potential for growth and innovation in the pharmaceutical sector. Positive drug data can lead to increased sales and market share, making this news crucial for both investors and patients who rely on effective treatments.
— Curated by the World Pulse Now AI Editorial System